Inovalon Holdings, Inc. (NASDAQ:INOV) President Robert A. Wychulis sold 85,828 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $15.54, for a total transaction of $1,333,767.12. Following the completion of the sale, the president now owns 466,286 shares in the company, valued at $7,246,084.44. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Inovalon Holdings, Inc. (INOV) opened at $15.30 on Friday. The stock has a market cap of $2,239.14, a P/E ratio of 73.10, a PEG ratio of 4.49 and a beta of 1.24. Inovalon Holdings, Inc. has a 1 year low of $8.60 and a 1 year high of $17.80. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.62 and a quick ratio of 5.62.
Inovalon (NASDAQ:INOV) last issued its quarterly earnings results on Wednesday, November 1st. The technology company reported $0.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.01. The firm had revenue of $115.90 million for the quarter, compared to the consensus estimate of $114.79 million. Inovalon had a net margin of 4.07% and a return on equity of 4.63%. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.10 EPS. equities research analysts forecast that Inovalon Holdings, Inc. will post 0.24 earnings per share for the current fiscal year.
Several equities research analysts recently commented on INOV shares. Morgan Stanley upgraded shares of Inovalon from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $9.00 to $14.00 in a research report on Tuesday, September 12th. TheStreet upgraded shares of Inovalon from a “d+” rating to a “c-” rating in a research report on Thursday, October 5th. Zacks Investment Research downgraded shares of Inovalon from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. ValuEngine upgraded shares of Inovalon from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Finally, KeyCorp reiterated a “hold” rating on shares of Inovalon in a research report on Tuesday, September 12th. Three analysts have rated the stock with a sell rating and six have given a hold rating to the stock. Inovalon presently has an average rating of “Hold” and an average target price of $12.00.
Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA lifted its position in shares of Inovalon by 336.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 8,397 shares of the technology company’s stock worth $110,000 after purchasing an additional 6,472 shares during the period. Advisor Group Inc. lifted its position in shares of Inovalon by 24.8% in the 2nd quarter. Advisor Group Inc. now owns 10,191 shares of the technology company’s stock worth $134,000 after purchasing an additional 2,023 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of Inovalon in the 2nd quarter worth approximately $154,000. Principal Financial Group Inc. acquired a new position in shares of Inovalon in the 2nd quarter worth approximately $157,000. Finally, Bank of Montreal Can lifted its position in shares of Inovalon by 0.4% in the 2nd quarter. Bank of Montreal Can now owns 14,006 shares of the technology company’s stock worth $184,000 after purchasing an additional 61 shares during the period. Hedge funds and other institutional investors own 28.09% of the company’s stock.
Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.
Receive News & Ratings for Inovalon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.